Pharmaceutical sponsor
Innovent Biologics (Suzhou) Co. Ltd. Clinical Trials
Studies where Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 45IgA Nephropathy (IgAN)
IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy
Part 1 is a Single Ascending Dose (SAD) study, and Part 2 is a Multiple Ascending Dose (MAD) study
- Trial name
- NCT07886476
- Testing
- IBI3034, Telitacicept
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Obesity and Overweight
A Study of IBI3046 in Participants With Overweight or Obesity
This study evaluates the safety, tolerability, pharmacokinetics and pharmacodynamics of IBI3046 in Chinese overweight or obese participants, comprising four phases: single ascending dose (SAD), multiple ascending dose (MAD)…
- Trial name
- NCT07809945
- Testing
- IBI3046
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Acute Gouty Arthritis
A Study of Efficacy and Safety of IBI3011 in Subjects With Acute Gouty Arthritis
It is a study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of recombinant Anti-IL-RAP humanized monoclonal antibody injection in subjects with acute gout flare
- Trial name
- NCT07842497
- Testing
- Compound Betamenth Group, IBI3011 GROUP
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Atopic Dermatitis
A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis
This study is expected to include approximately 520 patients with moderate to severe AD, and they will be randomly assigned to the treatment group (IBI3027) and the control group (Dupilumab Injection ) in a 1:1 ratio.
- Trial name
- NCT07754786
- Testing
- Dupilumab Injection, IBI3027
- Where
- China
- Volunteers
- 520 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Pancreatic Cancer
A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
This is a study of a Multicenter, Randomized, Double-Blind, Phase III Study of IBI343 Monotherapy Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Participants with Claudin (CLDN) 18.2-Positive, Locally…
- Trial name
- NCT07066098
- Testing
- IBI343
- Where
- China
- Volunteers
- 201 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Hypertension
A Study of IBI3016 in Japanese Participants
A phase I clinical study to evaluate the safety ,tolerability, pharmacokinetic and pharmocodynamic characteristics of a single subcutaneous does of IBI3016 in Japanese participants with mild to moderate hypertension.
- Trial name
- NCT07838220
- Testing
- IBI3016 Dose 4, IBI3016 Dose 3, IBI3016 Dose 2
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Sjögren's Disease
A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of IBI355 in participants with moderate-to-severe Sj?gren's disease (SjD).
- Trial name
- NCT07836660
- Testing
- Part B -Telitacicept, Part A - IBI355
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Relapsed or Refractory Multiple Myeloma
A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
The purpose of this study is to evaluate how well IBI3003 works when compared with the investigator's choice regimen (DPd or PVd or SVd)
- Trial name
- NCT07623798
- Testing
- Pomalidomide Capsules, Bortezomib for Injection, Daratumumab Injection (Subcutaneous Injection)
- Where
- China
- Volunteers
- 255 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Overweight, Healthy Participants
IBI3042 Study in Healthy Participants and Overweight or Obese Participants
This is a Phase 1 study of IBI3042, an investigational oral medicine being developed as a potential treatment for overweight and obesity. The study has two parts. Part A will evaluate single doses of IBI3042 in healthy adults.
- Conditions
- Overweight, Healthy Participants, Obesity
- Trial name
- NCT07793019
- Testing
- Orforglipron, IBI3042
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Multiple Myeloma
A Open-Label Phase in Participants With Multiple Myeloma
This is an open-label, multi-center phase II study of IBI3003 in combination with anti-CD38 monoclonal antibody in adult subjects with multiple myeloma.
- Trial name
- NCT07764861
- Testing
- Dexamethasone, IBI3003, Lenalidomide
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Completed, with results posted
All –Lung Neoplasms
Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC
Efficacy and Safety Evaluation of IBI308 in Patients with advanced or metastatic Non-squamous NSCLC
- Trial name
- NCT03607539
- Testing
- Sintilimab, Pemetrexed, Platinum
- Where
- China
- Volunteers
- 397 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Non-small Cell Lung Cancer
A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC
Clinical trial results demonstrate that anti-PD-1 antibodies prolonged OS to approximately 9 months compared with 6 months in docetaxel group.
- Trial name
- NCT03150875
- Testing
- IBI308, Docetaxel
- Where
- 2 sites in China
- Volunteers
- 290 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Squamous NSCLC
Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC
Efficacy and Safety Evaluation of IBI308 in Patients with Advanced or Recurrent Squamous NSCLC
- Trial name
- NCT03629925
- Testing
- Sintilimab, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 357 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Cancer, Solid Tumor
First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors
The purpose of this study is to determine the safety, tolerability and efficacy of IBI308 monotherapy or in combination with chemotherapy in patients with certain types of advanced solid tumors.
- Trial name
- NCT02937116
- Testing
- IBI308, IBI308\Cisplatinum\Pemetrexed, IBI308\cisplatin\gemcitabine
- Where
- China
- Volunteers
- 233 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Advanced/Metastatic Solid Malignancies
IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
The study is to evaluate preliminary anti-tumor activity (overall response rate, ORR) of IBI308 monotherapy in subjects with advanced/metastatic solid malignancies.
- Trial name
- NCT03568539
- Testing
- IBI308
- Where
- 7 sites in United States
- Volunteers
- 39 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.